DOI QR코드

DOI QR Code

Estudy the Effect of Breast Cancer on Tlr2 Expression in Nb4 Cell

  • Amirfakhri, Siamak (Biological Science Department, University of Essex) ;
  • Salimi, Arsalan (Biological Science Department, University of Essex) ;
  • Fernandez, Nelson (Biological Science Department, University of Essex)
  • Published : 2016.01.11

Abstract

Background: Breast cancer is the most common neoplasm in women and the most frequent cause of death in those between 35 and 55 years of age. All multicellular organisms have an innate immune system, whereas the adaptive or 'acquired' immune system is restricted to vertebrates. This study focused on the effect of conditioned medium isolated from cultured breast cancer cells on NB4 neutrophil-like cells. Materials and Methods: In the current study neutrophil-like NB4 cells were incubated with MCF-7 cell-conditioned medium. After 6 h incubation the intracellular receptor TLR2, was analyzed. Results: The results revealed that MCF-7 cell-conditioned medium elicited expression of TLR2 in NB4 cells. Conclusions: This treatment would result in the production of particular stimulants (i.e. soluble cytokines), eliciting the expression of immune system receptors. Furthermore, the flow cytometry results demonstrated that MCF-7 cell-conditioned medium elicited an effect on TLR2 intracellular receptors.

Keywords

Breast neoplasms;serum;antigens;CD14;gene expression

References

  1. Aderem A, Ulevitch RJ (2000). Toll-like receptors in the induction of the innate immune response. Nature, 406, 782-7. https://doi.org/10.1038/35021228
  2. Akira S, Uematsu S, Takeuchi O (2006). Pathogen recognition and innate immunity. Cell, 124, 783-801. https://doi.org/10.1016/j.cell.2006.02.015
  3. Baggiolini M, Walz A, Kunkel SL (1989). Neutrophil-activating peptide-1/interleukin 8, a novel cytokine that activates neutrophils. J Clin Invest, 84, 1045-9. https://doi.org/10.1172/JCI114265
  4. Cassatella MA (1995). The production of cytokines by polymorphonuclear neutrophils. Immunol Today, 16, 21-6. https://doi.org/10.1016/0167-5699(95)80066-2
  5. Cassatella MA, Gasperini S, Russo MP (1997). Cytokine expression and release by neutrophils. Ann N Y Acad Sci, 832, 233-42. https://doi.org/10.1111/j.1749-6632.1997.tb46251.x
  6. Chedid M, Rubin JS, Csaky KG, et al (1994). Regulation of keratinocyte growth factor gene expression by interleukin 1. J Biol Chem, 269, 10753-7.
  7. Chen R, Alvero AB, Silasi DA, et al (2007). Inflammation, cancer and chemoresistance: taking advantage of the tolllike receptor signaling pathway. Am J Reprod Immunol, 57, 93-107. https://doi.org/10.1111/j.1600-0897.2006.00441.x
  8. Coussens LM, Werb Z (2002). Inflammation and cancer. Nature, 420, 860-7. https://doi.org/10.1038/nature01322
  9. Cross A, Bucknall RC, Cassatella MA, et al (2003). Synovial fluid neutrophils transcribe and express class II major histocompatibility complex molecules in rheumatoid arthritis. Arthritis Rheum, 48, 2796-806. https://doi.org/10.1002/art.11253
  10. Droemann D, Albrecht D, Gerdes J, et al (2005). Human lung cancer cells express functionally active Toll-like receptor 9. Respir Res, 6, 1. https://doi.org/10.1186/1465-9921-6-1
  11. El-Omar EM, Ng MT, Hold GL (2008). Polymorphisms in Tolllike receptor genes and risk of cancer. Oncogene, 27, 244-52. https://doi.org/10.1038/sj.onc.1210912
  12. Fearon DT, Locksley RM (1996). The instructive role of innate immunity in the acquired immune response. Science, 272, 50-3. https://doi.org/10.1126/science.272.5258.50
  13. Feiken E, Romer J, Eriksen J, et al (1995). Neutrophils express tumor necrosis factor-alpha during mouse skin wound healing. J Invest Dermatol, 105, 120-3. https://doi.org/10.1111/1523-1747.ep12313429
  14. Giatromanolaki A, Sivridis E, Simopoulos C, et al (2002). Differential assessment of angiogenic activity and of vascular survival ability (VSA) in breast cancer. Clin Exp Metastasis, 19, 673-9. https://doi.org/10.1023/A:1021354028685
  15. Goddard AD, Borrow J, Freemont PS, et al (1991). Characterization of a zinc finger gene disrupted by the t(15;17) in acute promyelocytic leukemia. Sci, 254, 1371-4. https://doi.org/10.1126/science.1720570
  16. Hallman M, Ramet M, Ezekowitz RA (2001). Toll-like receptors as sensors of pathogens. Pediatr Res, 50, 315-21. https://doi.org/10.1203/00006450-200109000-00004
  17. Hassan F, Islam S, Tumurkhuu G, et al (2006). Intracellular expression of toll-like receptor 4 in neuroblastoma cells and their unresponsiveness to lipopolysaccharide. BMC Cancer, 6, 281. https://doi.org/10.1186/1471-2407-6-281
  18. Huang B, Zhao J, Li H, et al (2005). Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res, 65, 5009-14. https://doi.org/10.1158/0008-5472.CAN-05-0784
  19. Hubner G, Brauchle M, Smola H, et al (1996). Differential regulation of pro-inflammatory cytokines during wound healing in normal and glucocorticoid-treated mice. Cytokine, 8, 548-56. https://doi.org/10.1006/cyto.1996.0074
  20. Ilvesaro JM, Merrell MA, Swain TM, et al (2007). Toll like receptor-9 agonists stimulate prostate cancer invasion in vitro. Prostate, 67, 774-81. https://doi.org/10.1002/pros.20562
  21. Imai Y, Kubota Y, Yamamoto S, et al (2005). Neutrophils enhance invasion activity of human cholangiocellular carcinoma and hepatocellular carcinoma cells: an in vitro study. J Gastroenterol Hepatol, 20, 287-93. https://doi.org/10.1111/j.1440-1746.2004.03575.x
  22. Janeway CA, Jr. (1989a). Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb Symp Quant Biol, 54, 1-13. https://doi.org/10.1101/SQB.1989.054.01.003
  23. Janeway CA, Jr. (1989b). Introduction: T-cell:B-cell interaction. Semin Immunol, 1, 1-3.
  24. Janeway CA, Jr. (1989c). The priming of helper T cells. Semin Immunol, 1, 13-20.
  25. Janeway CA, Jr., Medzhitov R (2002). Innate immune recognition. Annu Rev Immunol, 20, 197-216. https://doi.org/10.1146/annurev.immunol.20.083001.084359
  26. Kohen R, Nyska A (2002). Oxidation of biological systems: oxidative stress phenomena, antioxidants, redox reactions, and methods for their quantification. Toxicol Pathol, 30, 620-50. https://doi.org/10.1080/01926230290166724
  27. Kurt-Jones EA, Mandell L, Whitney C, et al (2002). Role of toll-like receptor 2 (TLR2) in neutrophil activation: GM-CSF enhances TLR2 expression and TLR2-mediated interleukin 8 responses in neutrophils. Blood, 100, 1860-8.
  28. Lee JS, Kim HS, Jung JJ, et al (2002). Expression of vascular endothelial growth factor in invasive ductal carcinoma of the breast and the relation to angiogenesis and p53 and HER-2/neu protein expression. Appl Immunohistochem Mol Morphol, 10, 289-95.
  29. Liu-Bryan R, Pritzker K, Firestein GS, et al (2005). TLR2 signaling in chondrocytes drives calcium pyrophosphate dihydrate and monosodium urate crystal-induced nitric oxide generation. J Immunol, 174, 5016-23. https://doi.org/10.4049/jimmunol.174.8.5016
  30. Lubbert M, Koeffler HP (1988). Myeloid cell lines: tools for studying differentiation of normal and abnormal hematopoietic cells. Blood Rev, 2, 121-33. https://doi.org/10.1016/0268-960X(88)90034-3
  31. Means TK, Golenbock DT, Fenton MJ (2000). Structure and function of Toll-like receptor proteins. Life Sci, 68, 241-58. https://doi.org/10.1016/S0024-3205(00)00939-5
  32. Medzhitov R, Janeway CA, Jr. (1998). Innate immune recognition and control of adaptive immune responses. Semin Immunol, 10, 351-3. https://doi.org/10.1006/smim.1998.0136
  33. Medzhitov R, Preston-Hurlburt P, Janeway CA, Jr. (1997). A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature, 388, 394-7. https://doi.org/10.1038/41131
  34. Nathan C (2006). Neutrophils and immunity: challenges and opportunities. Nat Rev Immunol, 6, 173-82. https://doi.org/10.1038/nri1785
  35. O'Neill L (2000). The Toll/interleukin-1 receptor domain: a molecular switch for inflammation and host defence. Biochem Soc Trans, 28, 557-63. https://doi.org/10.1042/bst0280557
  36. Ohashi K, Burkart V, Flohe S, et al (2000). Cutting edge: heat shock protein 60 is a putative endogenous ligand of the tolllike receptor-4 complex. J Immunol, 164, 558-61. https://doi.org/10.4049/jimmunol.164.2.558
  37. Olewniczak S, Chosia M, Kwas A, et al (2002). Angiogenesis and some prognostic parameters of invasive ductal breast carcinoma in women. Pol J Pathol, 53, 183-8.
  38. Pham CT (2006). Neutrophil serine proteases: specific regulators of inflammation. Nat Rev Immunol, 6, 541-50. https://doi.org/10.1038/nri1841
  39. Sato Y, Goto Y, Narita N, et al (2009). Cancer cells expressing toll-like receptors and the tumor microenvironment. Cancer Microenviron, 2, 205-14. https://doi.org/10.1007/s12307-009-0022-y
  40. Scapini P, Lapinet-Vera JA, Gasperini S, et al (2000). The neutrophil as a cellular source of chemokines. Immunol Rev, 177, 195-203. https://doi.org/10.1034/j.1600-065X.2000.17706.x
  41. Silverman MN, Pearce BD, Biron CA, et al (2005). Immune modulation of the hypothalamic-pituitary-adrenal (HPA) axis during viral infection. Viral Immunol, 18, 41-78. https://doi.org/10.1089/vim.2005.18.41
  42. Smith JA (1994). Neutrophils, host defense, and inflammation: a double-edged sword. J Leukoc Biol, 56, 672-86. https://doi.org/10.1002/jlb.56.6.672
  43. So EY, Ouchi T (2010). The application of Toll like receptors for cancer therapy. Int J Biol Sci, 6, 675-81.
  44. Takeda K, Akira S (2005). Toll-like receptors in innate immunity. Int Immunol, 17, 1-14.
  45. Underhill DM, Ozinsky A, Hajjar AM, et al (1999). The Tolllike receptor 2 is recruited to macrophage phagosomes and discriminates between pathogens. Nature, 401, 811-5. https://doi.org/10.1038/44605
  46. Vabulas RM, Ahmad-Nejad P, Ghose S, et al (2002). HSP70 as endogenous stimulus of the Toll/interleukin-1 receptor signal pathway. J Biol Chem, 277, 15107-12. https://doi.org/10.1074/jbc.M111204200
  47. Xie W, Wang Y, Huang Y, et al (2009). Toll-like receptor 2 mediates invasion via activating NF-kappaB in MDAMB-231 breast cancer cells. Biochem Biophys Res Commun, 379, 1027-32. https://doi.org/10.1016/j.bbrc.2009.01.009
  48. Yu L, Chen S (2008). Toll-like receptors expressed in tumor cells: targets for therapy. Cancer Immunol Immunother, 57, 1271-8. https://doi.org/10.1007/s00262-008-0459-8
  49. Zeromski J, Mozer-Lisewska I, Kaczmarek M (2008). Significance of toll-like receptors expression in tumor growth and spreading: a short review. Cancer Microenviron, 1, 37-42. https://doi.org/10.1007/s12307-008-0005-4
  50. Zhang G, Ghosh S (2001). Toll-like receptor-mediated NFkappaB activation: a phylogenetically conserved paradigm in innate immunity. J Clin Invest, 107, 13-9.- https://doi.org/10.1172/JCI11837